
Hyung-il Kim, CEO of Dotter, Inc. gives a lecture on BRS at ICI in Israel.
At the ICI held in Israel, Hyung-il Kim, CEO of Dotter Inc. gave a lecture on the biodegradable stent BRS
DOTTER is a globally patented technology-based healthcare company that provides solutions for diagnosing and treating lesions that cause ischemic heart disease.
As a company established by a combination of cardiovascular specialists and the best experts in Korea and the world in the field of optical coherence tomography (OCT), we are designing and producing sophisticated biodegradable stents (BRS) that are 1/3 the thickness of competitors. In addition, we are mainly developing next-generation OCT equipment, which is optical imaging equipment that can create a synergistic effect for stent insertion.
We aspire to diagnose and cure cardiovascular disease, the leading cause of mortality worldwide, using our unrivaled technological competitiveness, so that humankind can escape the pain of cardiovascular disease and enjoy a longer, healthier life.
Even now, while we pursue continuous technological innovation, we are focusing all our efforts and passion on ensuring the satisfaction of our customers and patients by prioritizing quality and safety.
Subscribe to our media mailing list and get updated with our most recent news
At the ICI held in Israel, Hyung-il Kim, CEO of Dotter Inc. gave a lecture on the biodegradable stent BRS
Dotter Inc. acquired the exclusive domestic rights to EluNIR™ through a recent contract with Israeli company Medinol.
EluNIR™ is scheduled to be marketed in Korea early next year through Dotter.
info@dotter.com